Biogen (BIIB) Comments to Truist Analyst About Billy Dunn

March 15, 2021 5:17 PM EDT
Get Alerts BIIB Hot Sheet
Price: $270.31 -0.05%

Rating Summary:
    16 Buy, 19 Hold, 5 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Truist Research analyst Robyn Karnauskas asked Biogen (NASDAQ: BIIB) two questions related to Billy Dunn and received a response from mangaement.

1) is Billy Dunn still at FDA?

  • As far as mgmt knows, Billy Dunn is still listed as Director of the Office of Neuroscience

2) Billy Dunn is still involved in the adu application process

  • the company is unable to comment any further

For those unaware, Dunn has been accused of inappropriate close collaboration with Biogen by an advocacy group.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Trader Talk

Related Entities